Rephonic
Artwork for Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers: Practice-Changing Cancer Discussions

Oncology Brothers
Immunotherapy
Non-Small Cell Lung Cancer
Chemotherapy
Multiple Myeloma
Acute Myeloid Leukemia
Renal Cell Carcinoma
Neuroendocrine Tumors
Breast Cancer
Her2-Positive Breast Cancer
Hepatocellular Carcinoma
Bladder Cancer
Small Cell Lung Cancer
Diffuse Large B-Cell Lymphoma
Nivolumab
Pancreatic Cancer
Clinical Trials
Chronic Myeloid Leukemia
Prostate Cancer
Colorectal Cancer
FDA Approval

The Oncology Brothers Podcast, led by Drs. Rahul and Rohit Gosain, is dedicated to bridging the gap between academic cancer centers and community oncology in the ever-evolving field of hematology & oncology. With a mission to disseminate crucial information to the medical community, this oncology podcast is not for medical advice but rather serves as a beacon for physicians, nurses, trainees, and ... more

PublishesDailyEpisodes100Founded4 years ago
Number of ListenersCategories
MedicineHealth & Fitness

Listen to this Podcast

Artwork for Oncology Brothers: Practice-Changing Cancer Discussions

Latest Episodes

Welcome to the Oncology Brothers podcast! In this episode, we had the opportunity to dive deep into the treatment algorithm for myelofibrosis with Dr. Nico Gagelmann of Dana-Farber Cancer Institute.

Join us as we explored:

• The critical distinctio... more

Welcome back to the Oncology Brothers podcast! In this episode, we were joined by the MPN specialists Drs. Brandi Reeves and Naveen Pemmaraju, to discuss the treatment options for polycythemia vera (PV) and essential thrombocythemia (ET).

We dived d... more

Welcome to the Oncology Brothers podcast! In this episode, we dived into the recent approval of rusfertide for polycythemia vera, based on the findings from the VERIFY study. We were joined by Dr. Andrew Kuykendall, an MPN specialist from the Moffitt... more

Welcome to the Oncology Brothers podcast! In this episode, we are joined by Dr. Aaron Gerds, a hematologist from the Cleveland Clinic, to discuss the current treatment algorithms for myeloproliferative neoplasms (MPNs), specifically focusing on polyc... more

Key Facts

Accepts Guests
Contact Information
Podcast Host
Number of Listeners
Find out how many people listen to this podcast per episode and each month.

Similar Podcasts

People also subscribe to these shows.

Recent Guests

Sagar Lonial
Myeloma specialist, first author of the EXCALIBER study
Emory University
Episode: EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Alicia Morgans
GU medical oncologist
Dana-Farber Cancer Center
Episode: Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer
Chris Pieczonka
Urologist
US Urology Partners
Episode: Managing Toxicities of Androgen Receptor Pathway Inhibitor (ARPI) in Prostate Cancer
Amer Zeidan
Hematology/Oncology physician from Yale School of Medicine
Yale School of Medicine
Episode: Challenging Cases in Myelodysplastic Syndrome (MDS) - Dr. Amer Zeidan
Tom LeBlanc
Physician from Duke Cancer Institute
Duke Cancer Institute
Episode: Treatment Algorithm of Myelodysplastic Syndrome (MDS) in 2026 - Dr. Thomas LeBlanc
Timothy Brown
GI medical oncologist from UT Southwestern
UT Southwestern
Episode: Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Kline
Heather Klein
GI-focused nurse practitioner from UT Southwestern
UT Southwestern
Episode: Pancreatic Cancer Management - Partners in Practice with Dr. Tim Brown & Ms. Heather Kline
Max Merz
Myeloma specialist from Memorial Sloan Kettering
Memorial Sloan Kettering Cancer Center
Episode: Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)
Shaji Kumar
Senior author of Endurance Trial, expert in myeloma
Mayo Clinic
Episode: ENDURANCE Trial - Time-limited Lenalidomide Maintenance for Standard Risk Myeloma

Hosts

Rahul Gosain
Co-host of the Oncology Brothers Podcast; physician specializing in oncology with clinical practice in community setting
Rohit Gosain
Co-host of the Oncology Brothers Podcast; physician specializing in oncology with clinical practice in community setting

Reviews

4.8 out of 5 stars from 114 ratings
  • Oncology Brothers: Setting a New Standard in Medical Education

    The Oncology Brothers have become a go-to in my week. They take the constant firehose of oncology data—new FDA approvals, shifting algorithms, and “practice-changing” abstracts—and turn it into something practical I can actually use in clinic the next day. The conversations feel like sitting down with smart colleagues who care about evidence, clarity, and real-world decision making, not just reciting trial slides. It’s exactly the kind of thoughtful, high-yield education our field needs more of.... more

    Apple Podcasts
    5
    DD1384
    United States8 months ago
  • Excellent Resource

    I regularly listen to this podcast and find it an excellent reference for oncology practice. The speakers consistently provide valuable insights that are both practical and informative. It's a great resource for staying updated and enhancing clinical knowledge.

    Apple Podcasts
    5
    RHJ, MD
    United Statesa year ago
  • Insightful, relatable, and essential for anyone in the oncology community

    The Oncology Brothers consistently deliver relevant, easy-to-digest insights on complex data and evolving treatment landscapes. Their ability to break down key updates—especially for those who can't attend every conference—is incredibly valuable. A must-listen for anyone in oncology looking to stay current and connected to the community.

    Apple Podcasts
    5
    OncoScriber
    United Statesa year ago
  • Stage IV CRC

    Thank you so much for putting this together! Love the updates of ongoing research! I am the primary caretaker for my 79 year old dad who was diagnosed 6/24 with stage IV CRC MSS KRAS G13D TMB-H, so love your GI updates from ASCO ‘25 and subcutaneous nivo, which we are considering. Hope you do more like bot/bal and neodadjuvant single cycle pembro. Thanks for taking the time to do this!!

    Apple Podcasts
    5
    mama4travel
    United States2 years ago
  • Onc Doc in the communty

    I have been following your content on X/Twitter and now I love that I can access these interviews here. Great work, much appreciated when things are moving so fast in this field.

    Apple Podcasts
    5
    Jimzz24
    United States2 years ago

Listeners Say

Key themes from listener reviews, highlighting what works and what could be improved about the show.

Audience notes the hosts' clear communication and evidence-based approach
Community oncologists appreciate real-world sequencing and toxicity management guidance
Physicians praise practical, high-yield education that translates to day-to-day practice
Listeners value concise updates on rapidly evolving oncology data

Chart Rankings

How this podcast ranks in the Apple Podcasts, Spotify and YouTube charts.

Talking Points

Recent interactions between the hosts and their guests.

EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Q: How should we monitor MRD in community settings after EXCALIBER approval?
MRD testing is increasingly requested; clinicians should aim to obtain baseline samples at diagnosis and perform MRD assessments periodically, though routine quarterly testing is not recommended—annual testing or MRD-driven decisions may be more appropriate.
EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Q: What are the practical considerations for integrating ibertamide into practice, including maintenance and sequencing?
Consideration includes where ibertamide fits after first relapse, potential sequencing with lenalidomide versus ibertamide, and whether combinations with proteasome inhibitors or immunotherapies are pursued; MRD-driven decisions may guide escalation or discontinuation.
EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Q: Who is the right patient for ibertamide today, given the current landscape with CAR-T and bispecifics?
Early relapse patients with access and logistical considerations may benefit; ibertamide offers an oral option with potentially less infectious risk and easier administration, particularly for those who can't access or tolerate CAR-T or bispecifics, though head-to-head data are needed.
EXCALIBER-RRMM - Iberdomide/Dara/Dex FDA Approval for R/R Multiple Myeloma: Dr. Sagar Lonial
Q: Sagar, could you go over what we are learning from EXCALIBER in relapsed/refractory multiple myeloma?
EXCALIBER followed FDA-dose optimization, then evaluated MRD and PFS as co-primary endpoints. It showed higher MRD negativity with ibertamide plus dara and dex compared to standard therapy, supporting accelerated approval and highlighting MRD as a meaningful efficacy marker in myeloma.
Treatment Algorithm of Late Relapsed/Refractory Multiple Myeloma (RRMM)
Q: But what next? What should we do for refractory disease after second, third, fourth line?
The next steps depend heavily on antigen expression after prior therapies; if BCMA remains expressed, BCMA-targeted strategies remain viable, but if BCMA is lost, we pivot to alternative targets such as GPRC5D or non-BCMA regimens, with careful consideration of prior toxicities and lines of therapy.

Audience Metrics

Listeners, social reach, demographics and more for this podcast.

Listeners per Episode
Gender Skew
Location
Interests
Professions
Age Range
Household Income
Social Media Reach

Frequently Asked Questions About This Podcast

What is This Podcast about and what kind of topics does it cover?

A concise, practitioner-focused show that translates cutting-edge oncology data into practical guidance for community clinicians. Episodes frequently feature hematology/oncology specialists from top academic centers who discuss treatment sequencing, real-world toxicity management, and emerging therapies across cancers like multiple myeloma, DLBCL, AML, and solid tumors such as pancreatic and breast cancer. Dialogues center on translating conference highlights, trial data, and evolving guidelines into actionable decision-making for frontline and relapsed settings, with an emphasis on patient quality of life and team-based care. Noteworthy are the frequent cross-center collaborations, deep dives into sequencing decisions, and a clear aim to b... more

Where can I find podcast stats for this podcast?

Rephonic provides a wide range of podcast stats for this podcast. We scanned the web and collated all of the information that we could find in our comprehensive podcast database. See how many people listen to this podcast and access YouTube viewership numbers, download stats, audience demographics, chart rankings, ratings, reviews and more.

How many listeners does this podcast get?

Rephonic provides a full set of podcast information for four million podcasts, including the number of listeners. View further listenership figures for this podcast, including podcast download numbers and subscriber numbers, so you can make better decisions about which podcasts to sponsor or be a guest on. You will need to upgrade your account to access this premium data.

What are the audience demographics for this podcast?

Rephonic provides comprehensive predictive audience data for this podcast, including gender skew, age, country, political leaning, income, professions, education level, and interests. You can access these listener demographics by upgrading your account.

How many subscribers and views does this podcast have?

To see how many followers or subscribers this podcast has on Spotify and other platforms such as Castbox and Podcast Addict, simply upgrade your account. You'll also find viewership figures for their YouTube channel if they have one.

Which podcasts are similar to this podcast?

These podcasts share a similar audience with this podcast:

1. Two Onc Docs
2. Oncology Today with Dr Neil Love
3. Research To Practice | Oncology Videos
4. OncLive® On Air
5. Plenary Session

How many episodes of this podcast are there?

this podcast launched 4 years ago and published 100 episodes to date. You can find more information about this podcast including rankings, audience demographics and engagement in our podcast database.

How do I contact this podcast?

Our systems regularly scour the web to find email addresses and social media links for this podcast. We scanned the web and collated all of the contact information that we could find in our podcast database. But in the unlikely event that you can't find what you're looking for, our concierge service lets you request our research team to source better contacts for you.

Where can I see ratings and reviews for this podcast?

Rephonic pulls ratings and reviews for this podcast from multiple sources, including Spotify, Apple Podcasts, Castbox, and Podcast Addict.

View all the reviews in one place instead of visiting each platform individually and use this information to decide if a show is worth pitching or not.

How do I access podcast episode transcripts for this podcast?

Rephonic provides full transcripts for episodes of this podcast. Search within each transcript for your keywords, whether they be topics, brands or people, and figure out if it's worth pitching as a guest or sponsor. You can even set-up alerts to get notified when your keywords are mentioned.

What guests have appeared on this podcast?

Recent guests on this podcast include:

1. Sagar Lonial
2. Alicia Morgans
3. Chris Pieczonka
4. Amer Zeidan
5. Tom LeBlanc
6. Timothy Brown
7. Heather Klein
8. Max Merz

To view more recent guests and their details, simply upgrade your Rephonic account. You'll also get access to a typical guest profile to help you decide if the show is worth pitching.

Find and pitch the right podcasts

We help savvy brands, marketers and PR professionals to find the right podcasts for any topic or niche. Get the data and contacts you need to pitch podcasts at scale and turn listeners into customers.
Try it free for 7 days